I am writing to you in my role as the incoming editor for APA's Experimental and Clinical Psychopharmacology. I have identified your division as one that may have an interest in the journal's content. I have appended the updated scope for the journal below, but would like to draw your attention to the new submission types that we will be accepting at the journal: brief communications (no more than 3000 words, excluding references; no more than 2 total figures or tables), case reports (no more than 2000 words; only 1 figure or table) and brief reviews (no more than 5000 words, excluding references). The journal will continue to accept original research reports (no word limit, but should typically be 4-8000 words, excluding references) and full reviews (no word limit).
I hope you will consider submitting relevant manuscripts to the journal and that you will share this information with any potentially interested colleagues.
Please feel free to contact me directly at email@example.com if you have questions about Experimental and Clinical Psychopharmacology.
Experimental and Clinical Psychopharmacology
Experimental and Clinical Psychopharmacology ® publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse. The scope of research in these areas continues to expand and to benefit from collaborations across a broad range of disciplines, including behavioral science, biochemistry, brain imaging, genetics, medicine, neuroendocrinology, neuroscience, and pharmacology. The overall goal of Experimental and Clinical Psychopharmacology is to provide a forum for high-quality, innovative preclinical and clinical research that advances our understanding of the behavioral and biological determinants of the effects of centrally acting drugs.
The journal publishes original reports and brief communications on the development and evaluation of pharmacotherapies for a range of mental health diagnoses, the influence of genetics and hormones on responses psychoactive drugs, the pharmacological management of pain, and brain imaging studies of the neural correlates of psychoactive drug effects.
Rigorous preclinical and human laboratory studies, as well as controlled clinical trials of novel interventions, relevant to psychopharmacology and/or substance abuse, are particularly encouraged. The journal recommends that all submissions consider relevant biological variables (e.g., age, animal strain, sex) that may influence outcomes in study design and statistical analyses.
When appropriate (e.g., to provide initial clinical documentation of an emerging issue or topic in psychopharmacology and/or substance abuse), the journal will publish case reports. Case reports are expected to be thoughtful and thorough with attention paid to underlying etiology, behavioral, clinical, and laboratory findings. Any hypotheses should be supported by data and extant literature.
The journal will also include integrative reviews, both full and brief, of advances in research on psychopharmacology and/or substance abuse. Full reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches. Brief reviews should provide a scholarly perspective on a circumscribed topic or a novel area that has a relatively small number of relevant research studies to consider. It is recommended that authors contact the editor prior to review preparation regarding suitability for the journal.
Each year, the journal will recognize individuals who are recipients of awards from APA Division 28 (Psychopharmacology and Substance Abuse). Awardees will be invited to submit a full or brief review paper based on their award-winning research contributions.
William W. Stoops, Ph.D.
phone: (859) 257-5383
facsimile: (859) 257-7684
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science
STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.